Ocrelizumab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Ocrelizumab" in English language version.

refsWebsite

Global rank English rank

8nih.gov

4^th place

5fda.gov

447^th place

338^th place

4doi.org

2^nd place

2tga.gov.au

3,984^th place

2,622^nd place

2statnews.com

8,771^st place

5,253^rd place

2yahoo.com

38^th place

40^th place

1drugs.com

399^th place

333^rd place

1guildlink.com.au

low place

1hres.ca

low place

1canada.ca

1,712^th place

1,063^rd place

1medicines.org.uk

3,823^rd place

2,387^th place

1europa.eu

68^th place

117^th place

1semanticscholar.org

11^th place

8^th place

1soton.ac.uk

6,219^th place

4,029^th place

1handle.net

102^nd place

76^th place

1reuters.com

49^th place

47^th place

1medscape.com

719^th place

636^th place

canada.ca

"Neurological therapies". Health Canada. 9 May 2018. Retrieved 13 April 2024.

doi.org

McGinley MP, Moss BP, Cohen JA (January 2017). "Safety of monoclonal antibodies for the treatment of multiple sclerosis". Expert Opinion on Drug Safety. 16 (1): 89–100. doi:10.1080/14740338.2017.1250881. PMID 27756172. S2CID 36762194.
Bar-Or A, Calkwood JC, Chognot C, Evershed J, Fox EJ, Herman A, et al. (October 2020). "Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study". Neurology. 95 (14): e1999–e2008. doi:10.1212/WNL.0000000000010380. PMC 7843152. PMID 32727835.
Reddy V, Dahal LN, Cragg MS, Leandro M (August 2016). "Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?" (PDF). Drug Discovery Today. 21 (8): 1330–8. doi:10.1016/j.drudis.2016.06.009. PMID 27343722.
Sorensen PS, Blinkenberg M (January 2016). "The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects". Therapeutic Advances in Neurological Disorders. 9 (1): 44–52. doi:10.1177/1756285615601933. PMC 4710102. PMID 26788130.

drugs.com

"Ocrelizumab (Ocrevus) Use During Pregnancy". Drugs.com. 13 August 2019. Retrieved 28 March 2020.

europa.eu

ema.europa.eu

"Ocrevus EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 25 April 2020. This article incorporates text from this source, which is in the public domain.

fda.gov

New Drug Therapy Approvals 2017 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2018. Retrieved 16 September 2020.
"FDA approves new drug to treat multiple sclerosis". U.S. Food and Drug Administration (FDA) (Press release). 29 March 2017. Retrieved 25 April 2020. This article incorporates text from this source, which is in the public domain.
"Drug Trials Snapshots: Ocrevus". U.S. Food and Drug Administration (FDA). 28 March 2017. Retrieved 25 April 2020. This article incorporates text from this source, which is in the public domain.

accessdata.fda.gov

"Ocrevus (ocrelizumab) Injection". U.S. Food and Drug Administration (FDA). 9 May 2017. Retrieved 25 April 2020.
"BLA Approval Letter" (PDF). U.S. Food and Drug Administration (FDA). 28 March 2017.

guildlink.com.au

"Ocrevus PI" (PDF). Retrieved 31 March 2024.

handle.net

hdl.handle.net

World Health Organization (2006). "International nonproprietary names for pharmaceutical substances (INN) : recommended international nonproprietary names (Rec. INN) : list 56". WHO Drug Information. 20 (3): 220. hdl:10665/73839.

hres.ca

hpr-rps.hres.ca

"Regulatory Decision Summary for Ocrevus". Drug and Health Product Register. 23 October 2014.

medicines.org.uk

"Ocrevus 300 mg concentrate for solution for infusion - Summary of Product Characteristics (SmPC)". (emc). 30 December 2019. Retrieved 28 March 2020.

medscape.com

"First Data From Ocrelizumab Phase 3 Studies in MS. Oct 2015". Medscape Log.

nih.gov

pubmed.ncbi.nlm.nih.gov

McGinley MP, Moss BP, Cohen JA (January 2017). "Safety of monoclonal antibodies for the treatment of multiple sclerosis". Expert Opinion on Drug Safety. 16 (1): 89–100. doi:10.1080/14740338.2017.1250881. PMID 27756172. S2CID 36762194.
Bar-Or A, Calkwood JC, Chognot C, Evershed J, Fox EJ, Herman A, et al. (October 2020). "Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study". Neurology. 95 (14): e1999–e2008. doi:10.1212/WNL.0000000000010380. PMC 7843152. PMID 32727835.
Reddy V, Dahal LN, Cragg MS, Leandro M (August 2016). "Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?" (PDF). Drug Discovery Today. 21 (8): 1330–8. doi:10.1016/j.drudis.2016.06.009. PMID 27343722.
Sorensen PS, Blinkenberg M (January 2016). "The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects". Therapeutic Advances in Neurological Disorders. 9 (1): 44–52. doi:10.1177/1756285615601933. PMC 4710102. PMID 26788130.
Hutas G (November 2008). "Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies". Current Opinion in Investigational Drugs. 9 (11): 1206–15. PMID 18951300.

ncbi.nlm.nih.gov

Bar-Or A, Calkwood JC, Chognot C, Evershed J, Fox EJ, Herman A, et al. (October 2020). "Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study". Neurology. 95 (14): e1999–e2008. doi:10.1212/WNL.0000000000010380. PMC 7843152. PMID 32727835.
Sorensen PS, Blinkenberg M (January 2016). "The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects". Therapeutic Advances in Neurological Disorders. 9 (1): 44–52. doi:10.1177/1756285615601933. PMC 4710102. PMID 26788130.

dailymed.nlm.nih.gov

"Ocrevus- ocrelizumab injection". DailyMed. 13 December 2019. Retrieved 25 April 2020.

reuters.com

Reid K (8 March 2010). "Update 2. Roche suspends arthritis treatment after deaths". Reuters.

semanticscholar.org

api.semanticscholar.org

McGinley MP, Moss BP, Cohen JA (January 2017). "Safety of monoclonal antibodies for the treatment of multiple sclerosis". Expert Opinion on Drug Safety. 16 (1): 89–100. doi:10.1080/14740338.2017.1250881. PMID 27756172. S2CID 36762194.

soton.ac.uk

eprints.soton.ac.uk

Reddy V, Dahal LN, Cragg MS, Leandro M (August 2016). "Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?" (PDF). Drug Discovery Today. 21 (8): 1330–8. doi:10.1016/j.drudis.2016.06.009. PMID 27343722.

statnews.com

Winslow R (28 March 2017). "After 40-year odyssey, first drug for aggressive MS wins FDA approval". STAT.
Nather D (19 February 2016). "New drug for severe form of MS generates glimmer of hope". STAT.

tga.gov.au

"Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 9 April 2023.
"Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.

yahoo.com

finance.yahoo.com

"Roche's OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis". Yahoo Finance. 25 June 2024. Retrieved 25 June 2024.
"Roche's OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis". Yahoo Finance. 25 June 2024. Retrieved 25 June 2024.